乳腺癌组织中耐药基因蛋白表达的相关研究

目的探讨多药耐药基因P-gp、LRP、TOPOⅡ在化疗前乳腺癌组织的表达及其与ER、PR、CerbB-2及淋巴结转移之间的相关性。方法采用免疫组化SP法检测76例乳腺癌组织中ER、PR、CerbB-2、P-gp、LRP、TOPOⅡ的表达水平。结果P-gp、LRP、TOPOⅡ在化疗前乳腺癌中的表达率分别为28.9%(22/76)、84.2%(64/76)和80.3%(61/76)。LRP、TOPOⅡ与CerbB-2之间存在正相关关系,LRP、TOPOⅡ与ER、PR之间无相关,P-gp与ER、PR及CerbB-2之间均无相关性。有无淋巴结转移对耐药相关基因LRP、P-gp、TOPOⅡ的表达无显著性影响。结论P-gp、LRP、TOPOⅡ与乳腺癌原发MDR的发生有相当关系,CerbB-2基因可能也参与了MDR基因的调节机制。

Objective To investigate the expression of mulfidmg resistance genes P-gp, LRP,TOPO Ⅱ in breast cancer before chemotherapy, and evaluate their relations with ER, PR, CerbB - 2 and lymphatic metastasis. Methods Immunohistochemical staining （S - P method ） was used to detect the expression of ER, PR, CerbB-2, P-gp, LRP,TOPOⅡ in 76 cases of breast cancer. Results The expression rate of P-gp, LRP,TOPOⅡ in breast cancer before chemotherapy was 28.9% （22/76）, 84.2% （64/76）, 80.3% （61/76） respectively, The expression of LRP, TOPO H and CerbB - 2 show positive correlation, The expression of LRP, TOPO H show no correlation with the expression of ER and PR, and the expression of P -gp also show no correlation with the expression of ER , PR and CerbB - 2. Lymphatic metastasis or not show no significant effect on the expression of LRP, TOPO Ⅱ and P - gp. Conclusion Genes P - gp, LRP, TOPO Ⅱmay be involved in the primary MDR of breast cancer and gene CerbB - 2 may correlate with the regulatory machanism of MDR genes.